Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albinterferon alfa-2b every 4 weeks plus ribavirin in treatment-naive genotype 2/3 chronic hepatitis C
2008-002039-34Phase 2Completed
- Sponsor
- Novartis
- Start
- Sep 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of albinterferon alfa-2b, ribavirin and peginterferon alfa-2a in hepatitis C virus infection (5 arms), sponsored by Novartis. Primary endpoint: Safety and tolerability of albinterferon alfa-2b every 4 weeks plus daily ribavirin. Started Sep 2008; status: completed.
02
Drugs
albinterferon alfa-2bribavirinpeginterferon alfa-2a
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2008-002039-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002039-34.